Overview of non-coding RNAs in breast cancers

Dabi, Yohann; Bendifallah, Sofiane; Suisse, Stéphane; Haury, Julie; Touboul, Cyril; Puchar, Anne; Favier, Amélia; Daraı̈, Émile

doi:10.1016/j.tranon.2022.101512

Cited by 7 publications

(5 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In that study, we found a lack of consistency in the circulating cfmiRNAs identified across various studies. Similar results have been described in previous reviews [14][15][16][17]. This lack of replication among studies could be attributed to several factors, such as variations in the methods used for selecting cfmiRNAs, the absence of standardized tech-niques (including differences in sample collection and preservation, laboratory methodologies, cfmiRNA measurement and normalization, and cut-off values), inconsistent patient selection, limited cfmiRNA abundance, small sample sizes, and inadequate statistical analysis.…”

Section: Discussionsupporting

confidence: 80%

See 1 more Smart Citation

Identifying MicroRNAs Suitable for Detection of Breast Cancer: A Systematic Review of Discovery Phases Studies on MicroRNA Expression Profiles

Padroni,

De Marco,

Fiano

et al. 2023

IJMS

View full text Add to dashboard Cite

The analysis of circulating tumor cells and tumor-derived materials, such as circulating tumor DNA, circulating miRNAs (cfmiRNAs), and extracellular vehicles provides crucial information in cancer research. CfmiRNAs, a group of short noncoding regulatory RNAs, have gained attention as diagnostic and prognostic biomarkers. This review focuses on the discovery phases of cfmiRNA studies in breast cancer patients, aiming to identify altered cfmiRNA levels compared to healthy controls. A systematic literature search was conducted, resulting in 16 eligible publications. The studies included a total of 585 breast cancer cases and 496 healthy controls, with diverse sample types and different cfmiRNA assay panels. Several cfmiRNAs, including MIR16, MIR191, MIR484, MIR106a, and MIR193b, showed differential expressions between breast cancer cases and healthy controls. However, the studies had a high risk of bias and lacked standardized protocols. The findings highlight the need for robust study designs, standardized procedures, and larger sample sizes in discovery phase studies. Furthermore, the identified cfmiRNAs can serve as potential candidates for further validation studies in different populations. Improving the design and implementation of cfmiRNA research in liquid biopsies may enhance their clinical diagnostic utility in breast cancer patients.

show abstract

Section: Discussionsupporting

confidence: 80%

“…The search for cfmiRNAs to use as diagnostic biomarkers in breast cancer is very active. Several reviews and meta-analyses have been published on the predictive role of cfmiRNAs in breast cancer diagnosis [13][14][15][16][17]. Nevertheless, all of them were based on validation phases of the study or on studies on candidate cfmiRNAs.…”

Section: Introductionmentioning

confidence: 99%

Identifying MicroRNAs Suitable for Detection of Breast Cancer: A Systematic Review of Discovery Phases Studies on MicroRNA Expression Profiles

Padroni,

De Marco,

Fiano

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…In summary, AKT3 does not appear to have pro-oncogenic effects, and it may exert partly contradictory effects, largely depending on the specific BC cell type (Table 2). Nonetheless, emerging studies have indicated that miRNAs have critical roles in BC tumorigenesis by interfering with the PI3K/AKT signaling pathway [52]. The regulation of the AKT3 expression by miRNAs and the functions of the miRNA/AKT3 axes in BC are summarized in Table 3.…”

Section: Breast Cancermentioning

confidence: 99%

The Multifunctional Nature of the MicroRNA/AKT3 Regulatory Axis in Human Cancers

Yang,

Hardy

2023

Cells

View full text Add to dashboard Cite

Serine/threonine kinase (AKT) signaling regulates diverse cellular processes and is one of the most important aberrant cell survival mechanisms associated with tumorigenesis, metastasis, and chemoresistance. Targeting AKT has become an effective therapeutic strategy for the treatment of many cancers. AKT3 (PKBγ), the least studied isoform of the AKT family, has emerged as a major contributor to malignancy. AKT3 is frequently overexpressed in human cancers, and many regulatory oncogenic or tumor suppressor small non-coding RNAs (ncRNAs), including microRNAs (miRNAs), have recently been identified to be involved in regulating AKT3 expression. Therefore, a better understanding of regulatory miRNA/AKT3 networks may reveal novel biomarkers for the diagnosis of patients with cancer and may provide invaluable information for developing more effective therapeutic strategies. The aim of this review was to summarize current research progress in the isoform-specific functions of AKT3 in human cancers and the roles of dysregulated miRNA/AKT3 in specific types of human cancers.

show abstract

“…Specifically, piRNAs are involved in the regulation of gene expression, which can lead to the abnormal growth and spread of cancer cells [26]. Several publications have established piRNAs' role in carcinogenesis [27][28][29]. An important fact is the possibility of preserving and transporting small RNA in the human body as part of exosomes and nanosized vesicles through the bloodstream [30][31][32][33].…”

Section: Introductionmentioning

confidence: 99%

Interactions of piRNAs with the mRNA of Candidate Genes in Esophageal Squamous Cell Carcinoma

Rakhmetullina,

Akimniyazova,

Niyazova

et al. 2023

CIMB

View full text Add to dashboard Cite

Recently, a database of human piRNAs (piwi-interacting RNAs) was created, which allows the study of the binding of many piRNAs to the mRNAs of genes involved in many diseases, including cancer. In the present work, we identified the piRNAs that can interact with candidate esophageal squamous cell carcinoma (ESCC) genes. The binding of 480 thousand piRNAs with the mRNAs of 66 candidate ESCC genes was studied. Bioinformatic studies found that piRNAs bind only to the mRNAs of nine candidate genes: AURKA, BMP7, GCOM1, ERCC1, MTHFR, SASH1, SIX4, SULT1A1, and TP53. It has been shown that piRNAs can bind to mRNA by overlapping nucleotide sequences in limited 3′UTR and 5′UTR regions called clusters of binding sites (BSs). The existence of clusters of piRNA BSs significantly reduces the proportion of the nucleotide sequences of these sites in the mRNA of target genes. Competition between piRNAs occurs for binding to the mRNA of target genes. Individual piRNAs and groups of piRNAs that have separate BSs and clusters of BSs in the mRNAs of two or more candidate genes have been identified in the mRNAs of these genes. This organization of piRNAs BSs indicates the interdependence of the expression of candidate genes through piRNAs. Significant differences in the ability of genes to interact with piRNAs prevent the side effects of piRNAs on genes with a lack of the ability to bind such piRNAs. Individual piRNAs and sets of piRNAs are proposed and recommended for the diagnosis and therapy of ESCC.

show abstract

Overview of non-coding RNAs in breast cancers

Cited by 7 publications

References 123 publications

Identifying MicroRNAs Suitable for Detection of Breast Cancer: A Systematic Review of Discovery Phases Studies on MicroRNA Expression Profiles

Identifying MicroRNAs Suitable for Detection of Breast Cancer: A Systematic Review of Discovery Phases Studies on MicroRNA Expression Profiles

The Multifunctional Nature of the MicroRNA/AKT3 Regulatory Axis in Human Cancers

Interactions of piRNAs with the mRNA of Candidate Genes in Esophageal Squamous Cell Carcinoma

Contact Info

Product

Resources

About